10/29
09:57 am
trml
Tourmaline Bio (NASDAQ:TRML) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Report
Tourmaline Bio (NASDAQ:TRML) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
9/15
08:07 am
trml
Tourmaline Bio (NASDAQ:TRML) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $35.00.
Medium
Report
Tourmaline Bio (NASDAQ:TRML) had its "market perform" rating reaffirmed by analysts at BMO Capital Markets. They now have a $48.00 price target on the stock, up previously from $35.00.
9/15
06:14 am
trml
Rating for TRML
Low
Report
Rating for TRML
9/15
06:14 am
trml
Rating for TRML
Low
Report
Rating for TRML
9/14
04:05 pm
trml
Tourmaline Bio downgraded to Market Perform from Outperform at BMO Capital
Low
Report
Tourmaline Bio downgraded to Market Perform from Outperform at BMO Capital
9/14
04:05 pm
trml
Tourmaline Bio downgraded to Market Perform from Outperform at BMO Capital
Low
Report
Tourmaline Bio downgraded to Market Perform from Outperform at BMO Capital